Abstract
Gliosarcoma (GSM) is a rare and aggressive type of brain tumour with limited treatment options and a poor prognosis. The present case series aimed to provide further insights into the clinical features, treatment outcomes, and prognosis of GSM. Medical records of 12 histologically confirmed cases of GSM were analysed from 2018 to 2022, revealing a male predominance and a median age of 54 years. The most common symptoms were headache and vomiting due to raised intracranial pressure. All patients underwent maximal safe resection followed by concurrent chemoradiation and adjuvant chemotherapy with Temozolomide (TMZ). KaplanMeier analysis showed a median Progression-free Survival (PFS) and overall survival of 8 and 12 months, respectively. The study revealed that the optimal treatment for primary GSM remains a therapeutic dilemma due to the rarity of the disease and the heterogeneity of the patient population and treatment regimens employed. The present study provides valuable insights into the clinical presentation and management of primary GSM in India and highlights the need for further research to improve outcomes for these patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
